Join us in Barcelona at the premier global gathering for experts in lung cancer and thoracic oncology.
Alexander Starodub, Medical Director of Oncology Clinical Trials at The Christ Hospital and Principal Investigator of our NAPISTAR 1-01 study, will present a trial-in-progress poster highlighting the key parameters of the study. The Phase 1/2 study is evaluating our lead program TUB-040, a first-in-class ADC targeting the NaPi2b antigen, in patients with platinum-resistant ovarian cancer or relapsed/refractory adenocarcinoma non-small cell lung cancer.
The high prevalence of NaPi2b expression in adenocarcinoma NSCLC highlights the potential of TUB-040 as a novel therapeutic strategy to address the significant unmet medical need in this indication.
